Page 11

References

Agren MS (1994) Gelatinase activity during wound healing. Br J Dermatol 131: 634-640

Amento,EP, Beck LS (1991) TGF-beta and wound healing. Ciba Found Symp 157: 115-23

Appleton I, Tomlinson A, Colville-Nash PR, Willoughby DA (1993) Temporal and spatial immunolocalization of cytokines in murine chronic granulomatous tissue. Implications for their role in tissue development and repair processes. Lab Invest 69: 405-14

Bowler PG, Duerden BI, Armstrong DG (2001) Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 14: 244-269

Benedetti L, Cortivo R, Berti T, et al (1993) Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats. Biomaterials 14: 1154-60

Bennett NT, Schultz GS (1993) Growth factors and wound healing: Part II. Role in normal and chronic wound healing. Am J Surg 166: 74-81

Brantigan CO (1996). The history of the understanding of growth factors in wound healing. Wounds 8: 78-90

Brown RL, Breeden MP, Greenhalgh DG (1994) PDGF and TGF-alpha act synergistically to improve wound healing in the genetically diabetic mouse." Journal of Surgical Research 56: 562-70

Bullen EC, Longaker MT, Updike DL, et al (1995) Tissue inhibitor of metalloproteases-1 is decreased and activated gelatinases are increased in chronic wounds. J Invest Dermatol 104: 236-240

Chen WY and Abatangelo, G (1999) Functions of hyaluronan in wound repair. Wound Rep Regen 7: 79-89

Clark R, Cullen B, McCulloch E, Feng-Yi C (2002) The ability of ORC/collagen to bind, protect and deliver growth factors. Presented at the European Wound Management Association Conference, Granada, Spain

Colletta V, Dioguardi D, Di Lonardo A, Maggio G, Torasso F (2003) A trial to assess the efficacy and tolerability of Hyalofill-F in non-healing venous leg ulcers. J Wound Care 12: 357-60

Cullen B, Watt PW, Lundqvist C, et al The role of oxidized regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action. Int J Biochem Cell Biol 34: 1544-56

Cullen B, Smith R, McCulloch E, Silcocok D & Morrison L (2002b) Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Rep Regen 10: 16-25

Curran, MP, Plosker PL (2002) Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers. BioDrugs 16: 439-55

Da Costa RM, Ribeiro Jesus FM, Aniceto C, Mendes M (1999) Randomized, double-blind, placebo-controlled, dose- ranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers." Wound Rep Regen 7: 17-25

Edmonds M , Foster A (2000) Hyalofill: a new product for chronic wound management. Diab Foot 3: 29-30

Fivenson DP, Faria DT, Nickoloff BJ et al (1997) Chemokine and inflammatory cytokine changes during chronic wound healing. Wound Rep and Regeneration 5: 310-322

Franks PJ, Moffatt CJ, Connolly M, et al (1995) Factors associated with healing leg ulceration with high compression. Age Ageing 24: 407-10

Fray MJ, Dickinson RP, Huggins JP, Occleston NL (2003) A Potent, Selective Inhibitor of Matrix Metalloproteinase-3 for the Topical Treatment of Chronic Dermal Ulcers. J Med Chem 46: 3514-3525

Grinnell F, Zhu M (1996) Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alpha1-proteinase inhibitor, and alpha2-macroglobulin. J Invest Dermatol 106: 335-41

Hirshberg J, Coleman J, Marchant B, Rees RS (2001) TGF-beta3 in the treatment of pressure ulcers: a preliminary report. Adv Skin Wound Care 14: 91-5

Malik IA, Zahid M, Haq S, Syed S, Moid I, Waheed I (1998) Effect of subcutaneous injection of granulocyte-macrophage colony stimulating factor (GM-CSF) on healing of chronic refractory wounds. Eur J Surg 164: 737-44

Marston WA, Hanft J, Norwood P, Pollak R (2003) The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 26: 1701-5

Moore K (2001) The scientific basis of wound healing. Advances in Tissue Banking 5: 379-397, Pub World Scientific Publishing Co. Pte. Ltd

Nagai MK, Embil JM (2002) Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers. Expert Opin Biol Ther 2: 211-8

Ortonne JP (1996) A controlled study of the activity of hyaluronic acid in the treatment of venous leg ulcers. J Dermatol Treat 7:75-81

O'Toole EA (2001) Extracellular matrix and keratinocyte migration. Clin Exp Dermatol. 2001 26:525-30

Roberts C, Mansbridge J (2002) The scientific basis and differentiating features of Dermagraft. Can J Plast Surg 10 Suppl A: 6A-13A

Robson M (1997) Wound Infection - A failure of wound healing caused by an imbalance of bacteria. Surg Clin North America 77: 637-50

Robson MC, Hill DP, Smith PD, et al (2000). Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response." Annals of Surgery 231: 600-611

Robson MC, Phillips TJ, Falanga V, et al (2001) Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Rep Regen 9: 347-52

Rudek MA, Venitz J, Figg WD (2002) Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy? Pharmacotherapy 22: 705-20

Schmidtchen A, Wolff H, Hansson C (2001) Differential proteinase expression by Pseudomonas aeruginosa derived from chronic leg ulcers. Acta Derm Venereol 81: 406-9

Schultz GS, Sibbald RG, Falanga V, et al (2003) Wound bed preparation: a systematic approach to wound management. Wound Rep Regen 11 Suppl 1:S1-S28

Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N (2003) Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers." Ostomy Wound Manage 49: 76-84

Soler PM, Wright TE, Smith PD, et al (1999) In vivo characterization of keratinocyte growth factor-2 as a potential wound healing agent." Wound Rep Regen 7: 172-8

Steed D L (1995) Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 21: 71-8

Steed DL, Goslen JB, Holloway GA, Malone JM, Bunt TJ, Webster MW (1992) Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care 15: 1598-604

Steffensen B, Hakkinen L, Larjava H (2001) Proteolytic events of wound-healing--coordinated interactions among matrix metalloproteinases (MMPs), integrins, and extracellular matrix molecules. Crit Rev Oral Biol Med 12: 373-98

Streit M, Braathen LR (2000) Apligraf--a living human skin equivalent for the treatment of chronic wounds. Int J Artif Organs 23: 831-3

Trengrove N, Stacey MC, McGechie DF, Stingemore NF, Mata S (1996). Qualitative bacteriology and leg ulcer healing. J Wound Care 5: 277-80

Trengove NJ, Stacey MC, MacAuley S, et al (1999) Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors." Wound Rep Regen 7: 442-52

Valencia IC, Falabella AF, Eaglstein WH (2000). Skin grafting. Dermatol Clin 18: 521-32

Vin F, Teot L, Meaume S (2002) The healing properties of Promogran in venous leg ulcers. J Wound Care 11: 335-341

West DC, Kumar S (1989) The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp Cell Res 183: 179-96

White, R.J. (2003). An historical overview of the use of silver in wound management. pp59-68 in The Silver Book, Ed. White R. J., pub MA Healthcare Ltd.

Winter G D (1962) Formation of the scab and the rate of epithelisation of superficial wounds in the skin of the young domestic pig. Nature 193: 293-94

Wright TE, Hill DP, Ko F, et al (2000) The effect of TGF-beta2 in various vehicles on incisional wound healing. Int J Surg Investig 2: 133-43

Xia YP, Zhao Y, Marcus J, et al. (1999) Effects of keratinocyte growth factor-2 (KGF-2) on wound healing in an ischaemia-impaired rabbit ear model and on scar formation. J Pathol 188: 431-8

Yager DR, Chen SM, Ward SI (1997) Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Rep Regen 5: 23-32

Previous page 1 2 3 4 5 6 7 8 9 10 11